No Data
TRANSCENTA-B (06628) announced the latest Business progress on its new LIV-1 ADCs for the antitumor effects in models of triple-negative breast cancer at the 2024 SABCS.
TRANSCENTA-B (06628) announced that the 2024 San Antonio Breast Cancer Symposium (SABCS)...
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Chuangsheng Group - B (06628.HK) repurchased 0.069 million shares on December 5th for 0.0497 million Hong Kong dollars.
On December 5th, Grayscale Group-B (06628.HK) announced that it spent 0.0497 million Hong Kong dollars to repurchase 0.069 million shares.
Chuangsheng Group-B (06628.HK) has seen the executive director, chairman and CEO Qian Xueming increase shareholding by 0.15 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on December 2, Glorious Resources (06628.HK) was acquired by executive director, chairman, and CEO Qian Xueming in the market on November 27-28, 2024, with an average price per share of HK$0.61-0.64, totaling 0.15 million shares, involving approximately HK$0.093 million. After the increase, Qian Xueming's latest shareholding number is 37.3505 million shares, and the shareholding ratio has risen from 8.52% to 8.56%.
On November 27, Chuangsheng Group-B (06628.HK) spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Gelonghui November 27丨Chuangsheng Group-B (06628.HK) announced that on November 27, it spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
No Data
